Morange PE - Search Results

1

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.

Tregouet DA, Schnabel R, Alessi MC, Godefroy T, Declerck PJ, Nicaud V, Munzel T, Bickel C, Rupprecht HJ, Lubos E, Zeller T, Juhan-Vague I, Blankenberg S, Tiret L, Morange PE; AtheroGene Investigators. Tregouet DA, et al. Among authors: morange pe. J Thromb Haemost. 2009 Jan;7(1):49-57. doi: 10.1111/j.1538-7836.2008.03221.x. J Thromb Haemost. 2009. PMID: 19017260 Free article.

2

Resistance to activated protein C--diagnostic strategy in a laboratory of haemostasis.

Aillaud MF, Succo E, Alessi MC, Gandois JM, Gallian P, Morange P, Juhan-Vague I. Aillaud MF, et al. Thromb Haemost. 1995 Oct;74(4):1197-8. Thromb Haemost. 1995. PMID: 8560435 No abstract available.

3

Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease.

Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Alessi MC, et al. Diabetes. 1997 May;46(5):860-7. doi: 10.2337/diab.46.5.860. Diabetes. 1997. PMID: 9133556

4

Acquired protein S deficiency, likely due to anti-PS autoantibodies, following a thrombotic event in a patient with a systemic lupus erythematosus.

Morange PE, Alessi MC, Barthet MC, Aillaud MF, Harlé JR, Piquet P, Juhan-Vague I. Morange PE, et al. Thromb Haemost. 1997 Nov;78(5):1416-7. Thromb Haemost. 1997. PMID: 9408030 No abstract available.

5

Protein S deficiency: different biological phenotypes according to the assays used.

Brunet D, Barthet MC, Morange PE, Alessi MC, Borgel D, Gandrille S, Aillaud MF, Juhan-Vague I. Brunet D, et al. Among authors: morange pe. Thromb Haemost. 1998 Feb;79(2):446-7. Thromb Haemost. 1998. PMID: 9493608 No abstract available.

6

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.

Charles MA, Morange P, Eschwège E, André P, Vague P, Juhan-Vague I. Charles MA, et al. Diabetes Care. 1998 Nov;21(11):1967-72. doi: 10.2337/diacare.21.11.1967. Diabetes Care. 1998. PMID: 9802752 Clinical Trial.

7

A three-generation family presenting five cases of homozygosity for the 20210 G to A prothrombin variant.

Morange PE, Barthet MC, Henry M, Fontanet H, Aillaud MF, Alessi MC, Juhan-Vague I. Morange PE, et al. Thromb Haemost. 1998 Nov;80(5):859-60. Thromb Haemost. 1998. PMID: 9843184 No abstract available.

8

Fibrinogen, obesity and insulin resistance.

Juhan-Vague I, Morange P, Renucci JF, Alessi MC. Juhan-Vague I, et al. Blood Coagul Fibrinolysis. 1999 Feb;10 Suppl 1:S25-8. Blood Coagul Fibrinolysis. 1999. PMID: 10070814 Review. No abstract available.

9

Activation of plasminogen activator inhibitor-1 synthesis by phorbol esters in human promyelocyte HL-60--roles of PCKbeta and MAPK p42.

Lopez S, Peiretti F, Morange P, Laouar A, Fossat C, Bonardo B, Huberman E, Juhan-Vague I, Nalbone G. Lopez S, et al. Thromb Haemost. 1999 Mar;81(3):415-22. Thromb Haemost. 1999. PMID: 10102471

10

Rapid detection of factor XIII Val34Leu by allele specific PCR.

Henry M, Morange PE, Canavy I, Alessi MC, Juhan-Vague I. Henry M, et al. Among authors: morange pe. Thromb Haemost. 1999 Mar;81(3):463. Thromb Haemost. 1999. PMID: 10102479 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters